Welcome to our dedicated page for Lucid Diagnostics SEC filings (Ticker: LUCD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Lucid Diagnostics Inc. filings document a commercial-stage medical diagnostics issuer focused on esophageal precancer detection, its public-company governance, and its capital structure. Its 8-K reports disclose operating results and business updates for EsoGuard and EsoCheck, Regulation FD communications, completed common stock offerings, shelf registration statement references, proceeds for working capital and general corporate purposes, and related exhibits.
Proxy materials cover annual meeting matters, director elections, board classification, and stockholder voting. Other material-event filings address board appointments, non-employee director compensation arrangements, indemnification agreements, and governance rights associated with holders of the company’s convertible secured promissory notes due 2029.
Sparks Ronald M reported acquisition or exercise transactions in this Form 4 filing.
Lucid Diagnostics director Ronald M. Sparks received an equity award of 123,000 shares of common stock on February 20, 2026. The shares were granted at a price of $0.00 per share as restricted stock under the company’s 2018 Equity Plan.
Following this grant, Sparks directly owns 320,460 shares of common stock. The restricted stock has a single vesting date of May 20, 2029 and is subject to forfeiture if the required service period is not completed, meaning he must remain in service through that date to retain the award.
SOKOLOV JACQUE J reported acquisition or exercise transactions in this Form 4 filing.
Lucid Diagnostics Inc. director Jacque J. Sokolov reported an equity award of 123,000 shares of Common Stock. The shares are restricted stock granted under the company’s 2018 Equity Plan and carry a single vesting date of May 20, 2029, subject to forfeiture if the required service is not completed.
After this grant, Sokolov directly holds 320,460 shares of Lucid Diagnostics common stock.
PALUMBO JOHN R reported acquisition or exercise transactions in this Form 4 filing.
Lucid Diagnostics Inc. director John R. Palumbo received a grant of 123,000 shares of common stock as a restricted stock award under the company’s 2018 Equity Plan. The award was granted at $0.00 per share and increases his directly held common stock to 338,000 shares.
The restricted stock has a single vesting date of May 20, 2029 and is subject to forfeiture if the required service period is not completed, meaning Palumbo must remain in the specified service role through that date for the shares to fully vest.
Lapidus Stanley reported acquisition or exercise transactions in this Form 4 filing.
Lucid Diagnostics Inc. director Stanley Lapidus received a grant of 123,000 shares of common stock as an equity award. The award was granted at no cash cost and increased his directly held shares to 337,392. The shares are restricted stock under the company’s 2018 Equity Plan with a single vesting date of May 20, 2029, and are subject to forfeiture if the required service period is not completed.
Lucid Diagnostics Inc. director James L. Cox reported an equity award of common stock. He acquired 123,000 shares of restricted stock at a grant price of $0.00 per share as a grant, award, or other acquisition under the company’s 2018 Equity Plan. These restricted shares have a single vesting date of May 20, 2029 and are subject to forfeiture if the required service period is not completed. Following this award, Cox directly holds a total of 405,120 shares of Lucid Diagnostics common stock.
Lucid Diagnostics Inc. reported that Chief Financial Officer Dennis M. McGrath acquired 470,000 shares of common stock through a restricted stock grant at a price of $0.00 per share. These shares vest in a single installment on May 20, 2029 and are subject to forfeiture if the required service period is not completed. Following this award, McGrath directly holds 1,813,569 shares of Lucid Diagnostics common stock.
Lucid Diagnostics Inc. reported that President and COO Shaun O'Neil acquired 620,000 shares of common stock through a restricted stock grant under the company’s 2018 Equity Plan. The restricted stock has a single vesting date of May 20, 2029 and is subject to forfeiture if the required service period is not completed. Following this award, O'Neil directly holds 1,446,763 shares of common stock.
Gordon Michael Adam reported acquisition or exercise transactions in this Form 4 filing.
Lucid Diagnostics Inc. reported that its General Counsel and Secretary, Gordon Michael Adam, received a grant of 300,000 shares of common stock on February 20, 2026. The award is structured as restricted stock that vests in full on May 20, 2029 and is subject to forfeiture if the required service period is not completed. Following this grant, Adam directly holds 1,000,000 shares of Lucid Diagnostics common stock.
PAVmed Inc. filed Amendment No. 6 to its Schedule 13D regarding its stake in Lucid Diagnostics Inc.. PAVmed reports beneficial ownership of 38,816,903 shares of Lucid common stock, representing 27.5% of the class, giving it significant influence over shareholder votes.
The filing notes sole voting power over 38,816,903 shares and sole dispositive power over 31,302,444 shares, including voting proxies obtained from other Lucid stockholders and officers. PAVmed also entered an Amendment Agreement granting its noteholder the right to receive 300,000 Lucid shares upon specified future events, subject to a beneficial ownership limitation.
Lucid Diagnostics (LUCD) furnished an update announcing it issued a press release with financial results for the fiscal quarter ended September 30, 2025 and a business update. The release was provided as Exhibit 99.1. The information was furnished under Items 2.02 and 7.01 and is not deemed “filed” for purposes of Section 18 of the Exchange Act, nor incorporated by reference unless specifically stated.